Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 7/20 | 0.36 |
| ▸ | GSK3A | P49840 | 10/20 | 0.35 |
| ▸ | GSK3B | P49841 | 10/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6731975 | 0.87 | GSK3A (0.47) | PARP1GSK3AGSK3B | |
| SCHEMBL6837082 | 0.80 | MEN1 (0.41) | MEN1KMT2APARP1PDE4A | |
| SCHEMBL9746697 | 0.77 | HTR2A (0.51) | MEN1KMT2A | |
| SCHEMBL6834809 | 0.76 | MEN1 (0.39) | AURKAMEN1KMT2APARP1PDE4A | |
| SCHEMBL6827905 | 0.76 | MEN1 (0.39) | AURKAMEN1KMT2APARP1PDE4A | |
| SCHEMBL6837959 | 0.72 | MEN1 (0.40) | AURKAMEN1KMT2APARP1PDE4A | |
| SCHEMBL6835431 | 0.71 | PARP1 (0.49) | AURKAMEN1KMT2APARP1PDE4A | |
| SCHEMBL18984975 | 0.68 | MEN1 (0.39) | AURKAMEN1KMT2APARP1PDE4A | |
| SCHEMBL6835175 | 0.68 | MCL1 (0.42) | MEN1KMT2APARP1PDE4A | |
| SCHEMBL7258425 | 0.68 | MCL1 (0.42) | MEN1KMT2APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040029879-A1 | Heterocycle carboxamides as antiviral agents | ANDERSON DAVID JOHN (US) | 2004-02-12 | — | — | US | disclosed |
| US-6624159-B2 | Herpes virus | PHARMACIA & UPJOHN COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20020025959-A1 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029879-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | AURKA 428/4885MEN1 2250/4885KMT2A 993/4885 |
| US-20020025959-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | AURKA 428/4885MEN1 2250/4885KMT2A 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.